Table 3.

Summary of the presented mechanisms.

Mechanism of Action	Potential Therapeutic Procedures
-Preventing the activation and expression of MMP-3, -Preventing the activation of microglial cells, -Occurrence of gene transrepression for TNF-α and IL-1β, -Promoting neurogenesis in adults, -Increasing tyrosine hydrolyses, increasing VMAT2, -Inhibiting apoptosis induction by phosphorylation of cofilin, -Reducing oxidative stress toxicity, -Increasing cell proliferation and differentiation, -Restoring initial LTP values	Prevention and treatment of neurodegenerative diseases
-Intensifying acetylcholine transferase activity, -Promoting acetylcholine production, -Reducing lactate dehydrogenase concentration	ALS prevention and treatment
-Decreasing the activation of HIF-1α factor, -Reducing Bcl/Bax gene expression	Treatment of complications due to organ ischemia
-Reducing ischemia-induced immunoreactivity increases in the first twenty-four hours, -Reducing microglial activation in the ischemic region	Treatment of ischemic strokes
-Enhancing p38MAPK intracellular expression, -Translocating GLUT-4, -Intensifying GPxR activity, reducing TRxR	Prevention of myocardial infarcts
-Self-regulating GLP-1R expression after acute ischemia, -Inhibiting macrophage recruitment	Prevention of complications of thromboembolism, vascular atherosclerosis
-Occurrence of gene transrepression for inflammatory factors (TNF-α, IL-1β, JNK-1, TLR-2, TLR-4, NF-κB, SOCS-3), -Activating PKA, preventing bronchial hyperactivity	Improvement in asthma control
-Relaxing bronchial smooth muscles, -Relaxing the muscle layer in the vascular bed, -Increasing mRNA expression for CD68 macrophages -Intensifying MCP-1, IL-6, IL-10 expression, -Decreasing SFTPB and SFTPC expression, increasing SFTPD expression	COPD treatment